Prostate Cancer

Mindfulness-Based Cognitive Therapy Ineffective in Advanced PCa

Mindfulness-Based Cognitive Therapy Ineffective in Advanced PCa

The researchers observed no significant changes in intervention outcomes or in engagement with mindfulness for men with PC.

Survival Benefit Linked With Adjuvant RT+ADT in Lymph Node + PCa

Survival Benefit Linked With Adjuvant RT+ADT in Lymph Node + PCa

Radiation treatment plus androgen deprivation therapy (ADT) after radical prostatectomy was associated with an overall survival benefit.

ADT Not Linked to Dementia in Nonmetastatic Prostate Cancer

ADT Not Linked to Dementia in Nonmetastatic Prostate Cancer

No increased risk of dementia for androgen deprivation therapy use versus nonuse.

Prostate Cancer Incidence Lower in HIV-Infected Men

Prostate Cancer Incidence Lower in HIV-Infected Men

By

HIV-infected men and women had lower incidences of colorectal and lung cancer compared with the general population.

Cancer Patients Benefit From Exercise During, After Treatment

Cancer Patients Benefit From Exercise During, After Treatment

At the end of 3 months, the exercise and diet group was walking 3 to 4 times more quickly in a timed walk test of about a quarter-mile than the usual care group.

Study: 5-ARIs Do Not Increase PCa Death Risk

Study: 5-ARIs Do Not Increase PCa Death Risk

By

New findings confirm previous reports.

Guidelines Developed for Prostate MRI After Negative Biopsy

Guidelines Developed for Prostate MRI After Negative Biopsy

High-quality prostate MRI should be strongly considered for any patient with a prior negative biopsy who is under evaluation for a repeat biopsy.

Adjuvant RT+ADT Linked With Survival Advantage in Lymph Node Positive PCa

Adjuvant RT+ADT Linked With Survival Advantage in Lymph Node Positive PCa

Radiation treatment plus androgen deprivation therapy (ADT) after radical prostatectomy was associated with an overall survival benefit.

Second Opinions Rarely Alter PCa Treatment Decisions

Second Opinions Rarely Alter PCa Treatment Decisions

Obtaining second opinions was not associated with changes in treatment choice or with improvements in how patients viewed their quality of cancer care.

Fewer Prostate Biopsies After USPSTF Limited PSA Screening

Fewer Prostate Biopsies After USPSTF Limited PSA Screening

Following the 2012 USPSTF recommendation against PSA screening in populations, rates of radical prostatectomy and biopsy have become significantly less common.

Biases Suspected in Prostate Cancer Risk Estimates

Biases Suspected in Prostate Cancer Risk Estimates

Incident prostate cancer cohorts were defined by examining men who were regularly screened from the placebo arms of two large prostate cancer prevention trials.

PSA Error in the SEER Database Lower Than Suspected

PSA Error in the SEER Database Lower Than Suspected

The error rate due to the implied decimal point used for prostate-specific antigen (PSA) results is substantially lower than previously noted.

Hypogonadism Ups Progression Risk in Men With Low-Risk PCa

Hypogonadism Ups Progression Risk in Men With Low-Risk PCa

By

New findings have potential implications regarding patient selection for active surveillance.

Statins Curb Insulin-Related Cancer Risk in Diabetes Patients

Statins Curb Insulin-Related Cancer Risk in Diabetes Patients

Insulin-sparing and insulin-sensitizing drugs should be the preferred treatment choices for patients with type 2 diabetes.

Exercise Training Improves Quality of Life for PCa Patients

Exercise Training Improves Quality of Life for PCa Patients

By

Patient motivation is pivotal to the success of exercise interventions, researchers noted.

Higher Grade PCa Found After AS vs Immediate RP

Higher Grade PCa Found After AS vs Immediate RP

Patients with low-risk prostate cancer who enter active surveillance have higher grade disease at prostatectomy.

Prostate Cancer Active Surveillance Rates Highest in Sweden

Prostate Cancer Active Surveillance Rates Highest in Sweden

By

In 2014, 91% of Swedish men with very low risk prostate cancer opted for active surveillance.

FDA Approves Enzalutamide Labeling Update

FDA Approves Enzalutamide Labeling Update

By

Labeling information will include data showing the drug reduces the risk of radiographic progression versus bicalutamide.

Smokeless Tobacco May Increase Prostate Cancer Mortality

Smokeless Tobacco May Increase Prostate Cancer Mortality

Smokeless tobacco "snus" users have high blood levels of nicotine which promotes cancer progression.

New Prostate Cancer Screening Algorithm Proposed

New Prostate Cancer Screening Algorithm Proposed

By

A PSA level of 1.5 ng/mL or higher should prompt primary care physicians to refer patients to a urologist for further evaluation.

Dementia Linked to Prostate Cancer ADT

Dementia Linked to Prostate Cancer ADT

By

The risk of dementia was 2-fold higher among ADT users.

Ipilimumab Does Not Increase Overall Survival in mCRPC

Ipilimumab Does Not Increase Overall Survival in mCRPC

A phase 3 study of ipilimumab among patients with metastatic, castration-resistant prostate cancer (mCRPC) did not meet its primary endpoint.

Alisertib May Help Treat Neuroendocrine Prostate Cancer

Alisertib May Help Treat Neuroendocrine Prostate Cancer

NEPC is an aggressive subtype of castration-resistant prostate cancer independent of androgen expression.

Obesity Linked With Prostate Cancer Death

Obesity Linked With Prostate Cancer Death

By

A body mass index of 30 kg/m2 or higher was was associated with 2-fold increased risk of dying from prostate cancer.

Therapeutic Sequences for mCRPC Probed

Therapeutic Sequences for mCRPC Probed

By

Researchers demonstrate a possible survival advantage by including cabazitaxel in sequences of new agents in the post-docetaxel setting.

Prostate Cancer Progression Risk Lower With Initial Degarelix Use

Prostate Cancer Progression Risk Lower With Initial Degarelix Use

By

Pooled analysis shows initial use of degarelix versus LHRH agonists was associated with improved PSA progression-free survival.

ALP Decline in Radium-223 Recipients Predicts Better Outcomes

ALP Decline in Radium-223 Recipients Predicts Better Outcomes

By

In a study, a drop in alkaline phosphatase level at 12 weeks compared with baseline was associated with a decreased risk of death and first symptomatic skeletal event.

Radiographic Progression of mCRPC Without Rising PSA

Radiographic Progression of mCRPC Without Rising PSA

By

In a PREVAIL trial post hoc analysis, nearly one fourth of men on enzalutamide had radiographic progression despite non-rising PSA.

PCa Deaths Rare Among Men With Benign 1st Biopsy and Low PSA

PCa Deaths Rare Among Men With Benign 1st Biopsy and Low PSA

By

After 20 years, the prostate cancer mortality rate was 0.7% for men with a PSA level of 10 ng/mL or less and benign initial biopsy results.

Use Metastasis-Free Survival as Proxy in Localized PCa Trials

Use Metastasis-Free Survival as Proxy in Localized PCa Trials

Metastasis-free survival correlates with overall survival in localized prostate cancer clinical trials.

Sign Up for Free e-newsletters